49 results on '"Colombo N."'
Search Results
2. TGFβ PATHWAY ACTIVATION IS A PREDICTOR OF PROGRESSION FREE AND OVERALL SURVIVAL IN ADVANCED HIGH-GRADE SEROUS OVARIAN CANCER ACCORDING TO THE SURGICAL AGGRESSIVENESS AND RATE OF CYTOREDUCTION OF DIFFERENT ONCOLOGIC CENTERS: EP814
3. Patient-centred outcomes in the phase 3 study ARIEL3 of rucaparib maintenance treatment in patients with platinum-sensitive, recurrent ovarian carcinoma: post hoc exploratory analyses by BRCA mutation status and patient age
4. Effect of progression-free interval (PFI) following penultimate platinum-based regimen on the efficacy of rucaparib maintenance treatment in patients with platinum-sensitive, recurrent ovarian carcinoma: an analysis from the phase 3 study ARIEL3
5. Bevacizumab combined with first-line carboplatin and paclitaxel for metastatic/recurrent/persistent cervical cancer: primary results from the global single-arm phase II CECILIA study
6. Maintenance olaparib after platinum-based chemotherapy in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: efficacy by the timing of surgery and residual tumour status following upfront or interval cytoreductive surgery in the Phase III SOLO1 trial
7. 393 Keynote-826: a phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer
8. 88 Cervical re-injection to improve sentinel lymph node detection in endometrial cancer
9. 33 Olaparib monotherapy versus (VS) chemotherapy for germline BRCA-mutated (GBRCAM) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (PTS): phase III solo3 trial
10. 19 A large, multicenter, retrospective study on efficacy and safety of stereotactic body radiotherapy (SBRT) in oligometastatic ovarian cancer (MITO RT1 study)
11. 2 Exploratory analysis of postprogression and patient-centered outcomes in ariel3: a phase 3, randomized, placebo-controlled study of rucaparib maintenance treatment in patients with recurrent ovarian carcinoma
12. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up†
13. Unmanipulated haploidentical bone marrow transplantation and post-transplant cyclophosphamide for hematologic malignanices following a myeloablative conditioning: an update
14. DLI after haploidentical BMT with post-transplant CY
15. Optimal treatment of early-stage ovarian cancer
16. Platinum versus platinum-combination chemotherapy in platinum-sensitive recurrent ovarian cancer: a meta-analysis using individual patient data
17. Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
18. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
19. Imaging in gynecological disease (8): ultrasound characteristics of recurrent borderline ovarian tumors
20. The need for accredited training in gynaecological oncology: a report from the European Network of Young Gynaecological Oncologists (ENYGO)
21. Conservative management of early-stage epithelial ovarian cancer: results of a large retrospective series
22. Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up †
23. Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
24. Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
25. Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval
26. Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6–12 months) subpopulation of OVA-301 phase III randomized trial
27. With time on our side? Task-dependent compensatory processes in graceful aging
28. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
29. Phase II of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer, previously treated with platinum and taxanes
30. Non-epithelial ovarian cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
31. A phase II, randomized trial of neo-adjuvant chemotherapy comparing a three-drug combination of paclitaxel, ifosfamide, and cisplatin (TIP) versus paclitaxel and cisplatin (TP) followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the Snap-02 Italian Collaborative Study
32. Analysis of gene expression identifies PLAB as a mediator of the apoptotic activity of fenretinide in human ovarian cancer cells
33. Surgical treatment of drug-resistant nocturnal frontal lobe epilepsy
34. Sleep-related hyperkinetic seizures: always a frontal onset?
35. Electroclinical, MRI and neuropathological study of 10 patients with nodular heterotopia, with surgical outcomes
36. Early predictors of peripheral neurotoxicity in cisplatin and paclitaxel combination chemotherapy
37. Early predictors of chemotherapy-induced peripheral neurotoxicity: SC216
38. Oxaliplatin (OXA) in patients (pts) with advanced ovarian cancer (AOC) after failure of topotecan (TOPO) and/or liposomal doxorubicin based chemotherapy: 1861
39. International Collaborative Ovarian Neoplasm Trial 1: A Randomized Trial of Adjuvant Chemotherapy in Women With Early-Stage Ovarian Cancer
40. International Collaborative Ovarian Neoplasm Trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm Trial: Two Parallel Randomized Phase III Trials of Adjuvant Chemotherapy in Patients With Early-Stage Ovarian Carcinoma
41. Focal cortical dysplasia: neuropathological subtypes, EEG, neuroimaging and surgical outcome
42. Randomized Controlled Trial of Single-Agent Paclitaxel Versus Cyclophosphamide, Doxorubicin, and Cisplatin in Patients With Recurrent Ovarian Cancer Who Responded to First-Line Platinum-Based Regimens
43. Multizentrische randomisierte Phase-II-Studie zu Oxaliplatin (OXA) oder Topotecan (TOPO) bei Patientinnen mit Platin-vorbehandeltem epithelialem Ovarial karzinom (EOC): 847
44. Randomized phase III trial of bleomycin, vindesine, mitomycin-C, and cisplatin (BEMP) versus cisplatin (P) in disseminated squamous-cell carcinoma of the uterine cervix: An EORTC Gynecological Cancer Cooperative Group study
45. Paclitaxel and Cisplatin in Ovarian Cancer
46. Inhibitory Circuits in Human Dysplastic Tissue
47. RANDOMISED TRIAL COMPARING DOXORUBICIN, PACLITAXEL (AT), VERSUS PACLITAXEL (T), AS SECOND LINE THERAPY FOR ADVANCED OVARIAN CANCER (AOC) PATIENTS IN EARLY PROGRESSION AFTER PLATINUM-BASED CHEMOTHERAPY.
48. ICON2 trial
49. Propofol anaesthesia in spontaneously breathing paediatric patients during magnetic resonance imaging
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.